Survey study of blinatumomab care delivery for pediatric B-cell acute lymphoblastic leukemia in the US

Blinatumomab has fundamentally shifted the treatment paradigm for pediatric B-cell acute lymphoblastic leukemia (B-ALL). However, the care delivery challenges in transitioning from an experimental agent on a clinical trial to widespread clinical implementation are unknown. A survey study among US member institutions of the Children’s Oncology Group (COG) across 44 states was conducted from February to March 2025 to characterize the clinical landscape of pediatric blinatumomab care-delivery practice and challenges from the perspective of treating centers. Of 195 active COG member institutions, 147 center completed the survey. Most centers were using blinatumomab as standard therapy for pediatric B-ALL, but many centers had no home care company options. The authors conclude that these findings suggest that home care delivery of pediatric blinatumomab represents a health care infrastructure issue that has implications for family burden, hospital resource burden, and the capacity to scale pediatric outpatient care delivery beyond blinatumomab.